AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 90 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT01506427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F-18] HX4
Description: A single dose of 10 mCi, injected intravenously.
Study NCT00706407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully integrated Uro-NIRS:UDS
Description: As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
Study NCT00003623 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multivitamin
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg No adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg Aluminum hydroxide adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV F subunit 135 μg MF59 adjuvant
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT02298179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study NCT03537742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alirocumab
Description: alirocumab 150mg Subcutaneous
Study NCT03537742 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match alirocumab
Study NCT00087022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: girentuximab
Description: Given IV
Study NCT00087022 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT04580433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Feeding
Description: The trial consists of a 1-week baseline weight stabilization period followed by a 5-week TRF intervention period.~Participants will be instructed to eat freely from 8 a.m. to 4 p.m. daily and fast from 4 p.m. to 8 a.m. the next day.
Study NCT02195232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Study NCT04611425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Patients will receive an infusion of Remimazolam for a maximum duration of 48 hours. The dose of Remimazolam will be adapted according to the ICU units protocol of analgesia-sedation management, based on validated scale (Richmond Assessment Sedation Scale). Owing to previous data gathered through a previous study in Japan, the initial dose of infusion will be within a 0.2-0.5 mg/min range. The dose of Remimazolam can be increased or decreased by 0.1mg/min when needed. The maximum dose of Remimazolam will be set at 1 mg/min.
Study NCT00801489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00801489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT00801489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim-sndz
Description: Given SC
Study NCT00801489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00801489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Given IV
Study NCT00801489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV
Study NCT00801489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03128021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levomilnacipran Pill
Description: Double-blinded, randomly assigned
Study NCT01013558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 0.15 microgram/kg/min continuous infusion.
Study NCT01013558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: continuous infusion
Study NCT03648489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Please refer to arm/group description
Study NCT03648489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Please refer to arm/group description
Study NCT03648489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK228
Description: Please refer to arm/group description
Study NCT04177771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Adjustable lens (LAL) and Light Delivery Device (LDD) - Pre-COVID Population
Description: Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments
Study NCT04177771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SofPort LI61AO IOL
Description: Control treatment group will receive SofPort LI61AO IOL
Study NCT04177771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis ZCB00 or ZTC150 IOL
Description: Control treatment group will receive Tecnis ZCB00 or ZTC150 IOL
Study NCT00003623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01025323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: DASH diet and exercise advice
Study NCT06759246 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: implant placement
Description: Placement of short implants for the rehabilitation of single-tooth edentulism in atrophic maxillae near the maxillary sinus.
Study NCT01025323 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: DASH diet, exercise with systematic instruction by a dietician and/or coordinator
Study NCT02730624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Description: 4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
Study NCT02937493 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lunar phases
Description: Observation if lunar phases had an influence on occurrence of IPV
Study NCT02520219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDP
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
Study NCT02520219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
Study NCT02520219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days.
Study NCT01023542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delayed, low-dose CNI
Description: immunosuppression
Study NCT04080297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral capsule of Q-122
Study NCT01023542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BU-CNI
Description: Immunosuppression
Study NCT01023542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BU-Everolimus
Description: Immunosuppression
Study NCT04690075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Management and Dietary Fiber
Description: Routine nutrition management and dietary fiber supplements based on recommendation for 12 weeks.
Study NCT04690075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Management
Description: Routine nutrition management for 12 weeks.
Study NCT06762418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMR+SME
Description: Patients will be asked to wear this removable appliance for 16 hours per day. The exapnsion screw is activated twice a week.
Study NCT03567616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; oral
Study NCT06762418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BAIMT+RME
Description: The elastics is worn 18 hours per day to achieve the sagittal correction. The RME appliance on the upper jaw is activated twice daily until achieving the required expansion.
Study NCT03142399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whey protein
Description: Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
Study NCT03142399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
Study NCT01644695 — intervention group
Intervention type: PROCEDURE
Intervention: Bony Anchoring Reinforcement System
Description: Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
Study NCT01426919 — intervention group
Intervention type: OTHER
Intervention: Head CT scan and blood draw within 12 hours of injury
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Study NCT01989780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Study NCT05838053 — intervention group
Intervention type: PROCEDURE
Intervention: Lobectomy with systemic lymph node dissection
Description: Lobectomy with hilar and mediastinal lymph node dissection is performed. Segmentectomy with hilar and mediastinal lymph node dissection is performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
Study NCT05838053 — intervention group
Intervention type: PROCEDURE
Intervention: Segmentectomy with systemic lymph node dissection
Description: Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.
Study NCT01388439 — intervention group
Intervention type: DRUG
Intervention: Oseltamivir
Description: Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants \< 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants \< 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
Study NCT04265508 — intervention group
Intervention type: OTHER
Intervention: Assessment of hemostatic profile
Description: To assess the hemostatic profile, platelet function was analyzed by multiple electrode aggregometry (MEA) using Multiplate (ADP-, ASPI- and TRAP-test) and thrombelastometry using ROTEM (EXTEM, INTEM, FIBTEM)
Study NCT04213703 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT01524003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy treatment of the uterine cervix
Study NCT01524003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposcopy
Description: Colposcopy, biopsy and LEEP based on the pathology results
Study NCT04720040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mind STIM
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT02524015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel physical therapy
Study NCT02524015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard physical therapy
Study NCT00218582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double Trouble in Recovery
Description: Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
Study NCT00218582 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard psychiatric day treatment
Description: Individual counseling, groups, medication
Study NCT01094314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo culture medium
Description: comparison between two types of embryo culture medium
Study NCT05734053 — intervention group
Intervention type: OTHER
Intervention: Nilotinib
Description: There was no treatment allocation. Patients administered Nilotinib by prescription could be enrolled.
Study NCT01122342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Description: Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
Study NCT04396769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLOW-PA
Description: Classes were designed to provide the opportunity to be physically activity at a moderate-vigorous level. Each station included exercise options to accommodate varying fitness levels and offer students choice. Heart rate monitors provided consistent biofeedback to students throughout the intervention. Participants were evaluated based on the number of minutes they spent each class between 60-80% of their maximal heart rate. Games were intermixed either as a station or as a break in the circuit (e.g. short game of tag half-way through the workout) to make physical activity enjoyable and engaging.
Study NCT04396769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PE class as usual
Description: PE teachers were instructed to teach class as usual. Research staff were not involved in class activities or instruction. In this school district PE class as usual includes sports-based instruction in which students learn the rules to games and then practice playing.
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: PET Scan with \[18F\]-Flutemetamol
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET
Description: PET Scan with \[18F\]-Flutemetamol
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological tests
Study NCT02196116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological tests
Study NCT03342573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosentyx
Description: Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
Study NCT02802241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02802241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: peppermint oil
Study NCT02080039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Study NCT02927925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will receive daratumumab 16 mg/kg as intravenous infusion.
Study NCT00902369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK106-001616
Description: Part1: Dose escalation Part2: Dose expansion
Study NCT00902369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03567616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Capsule; oral
Study NCT03567616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally; for participants over 75 years of age, dexamethasone could have been administered at a 20 mg dose \[qw\]
Study NCT02956044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexagliflozin
Description: Bexagliflozin tablets, 20 mg
Study NCT03141918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
Study NCT03141918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Curcumin
Description: The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day.